The latest update is out from MiNK Therapeutics ( (INKT) ).

On September 26, 2025, Mesoblast Limited announced that its allogeneic cell therapy products, including Ryoncil®, are designated as U.S. origin products and are not subject to tariffs on imported ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical ...

The authors found comparable results among patients in all 3 donor categories. For instance, the 2-year overall survival (OS) ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S ...

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem ...

This article explores how stem cell therapies and organoid models are advancing Alzheimer’s research. It highlights progress ...

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream ...

UCLA researchers have made strides in developing a stem cell gene therapy for alpha thalassemia major, a severe, inherited ...

CancerBuddy connects users through shared diagnoses and experiences, offering community when hospital walls feel especially ...

Aims To assess cytokine levels in peripheral blood and tears of patients after allogeneic haematopoietic stem cell ...